Study Stopped
Difficulty of inclusion
Impact of Heart Failure on Calcium Homeostasis and Mitochondrial Function in Human Skeletal Muscle
CALCICARD2
Evaluation of Calcium Homeostasis and Mitochondrial Function in Skeletal Muscle in Subjects With Heart Failure
1 other identifier
interventional
22
1 country
1
Brief Summary
The aim of this project is to investigate the impact of heart failure (HF) on calcium homeostasis, mitochondrial function and oxydative stress in human skeletal muscle. The role playing by circulating factors such as cytokines and catecholamines will also be evaluated. 24 HF patients wiil be enrolled in the study: 12 male volunteers with a fraction of ejection ≥ 50% and 12 male volunteers with a fraction of ejection ≤ 35%. They will be compared to 12 sedentary healthy male volunteers, matched on age and physical activity.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable heart-failure
Started Sep 2013
Longer than P75 for not_applicable heart-failure
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 12, 2013
CompletedStudy Start
First participant enrolled
September 18, 2013
CompletedFirst Posted
Study publicly available on registry
October 8, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 21, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
June 30, 2020
CompletedAugust 6, 2020
August 1, 2020
2.8 years
June 12, 2013
August 5, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
calcium homeostasis
Cell analysis
8 days
mitochondrial function
Cell analysis
8 days
Secondary Outcomes (1)
skeletal muscular function in two stages of heart failure
8 days
Study Arms (3)
Patients with heart failure (FEVG ≥ 50%)
EXPERIMENTALPatients with heart failure (FEVG ≥ 50%)
Patients with heart failure (FEVG ≤ 35%),
EXPERIMENTALPatients with heart failure (FEVG ≤ 35%),
Healthy Volunteers
OTHERHealthy Volunteers with no heart failure
Interventions
Eligibility Criteria
You may qualify if:
- \- BMI \< 30
You may not qualify if:
- Contra-indication to exercise testing performance and muscle biopsy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University Hospital, Montpellierlead
- Institut National de la Santé Et de la Recherche Médicale, Francecollaborator
- Ministry of Health, Francecollaborator
- National Cancer Institute, Francecollaborator
- Institut de Recherches Internationales Serviercollaborator
Study Sites (1)
physiologie clinique, hopital Arnaud de Villeneuve, 371 avenue du Doyen G;Giraud
Montpellier, 34295, France
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- BASIC SCIENCE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 12, 2013
First Posted
October 8, 2013
Study Start
September 18, 2013
Primary Completion
June 21, 2016
Study Completion
June 30, 2020
Last Updated
August 6, 2020
Record last verified: 2020-08